Article

Multifocals good choice for right patient

Multifocal intraocular lenses (IOLs) are a good choice for the right patient.

Multifocal intraocular lenses (IOLs) are a good choice for the right patient, according to Dr. Martin Leyland of the Royal Berkshire Hospital, presenting the third update of the Cochrane systemic review of multifocal vs. monofocal studies.

All the studies reviewed were randomized controlled trials. "I think there is a problem assessing multifocal lenses because there are two interventions. There is cataract surgery, and these patients tend to be happy with the outcome irrespective of what lens you put in. Then you put the lens in, so for any study to be valid you have to have a control group of monofocal lenses," said Dr Leyland.

Dr Leyland summarized the results 10 RCT studies and found that there was no difference in distance high contrast VA between the two types of lens, while UCVA for near vision was better with the multifocal. It was impossible to compare BCVA for near because the methodology varied so widely between studies. In each of the studies, contrast sensitivity was lower for multifocal IOLs.

"Whether the difference attained statistical sensitivity depended on the size of the study," said Dr Leyland. "But in every trial it was a small difference, much smaller than the 40 to 50%% reduction in contrast you would expect from the optics in a multifocal lens. There must be some sort of post perception processing to compensate for."

For glare and halo, monofocals were significantly better, while multifocal IOLs very significantly reduced spectacle dependence. In 34" of cases, multifocal patients did not need glasses at all.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.